Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time to target uric acid to retard CKD progression
Takanori Kumagai, Tatsuru Ota, Yoshifuru Tamura, et al.
Clinical and Experimental Nephrology (2016) Vol. 21, Iss. 2, pp. 182-192
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review
Usama A. Sharaf El Din, Mona M. Salem, Dina O. Abdulazim
Journal of Advanced Research (2016) Vol. 8, Iss. 5, pp. 537-548
Open Access | Times Cited: 367
Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD
Anand Srivastava, Arnaud D. Kazé, Ciaran J. McMullan, et al.
American Journal of Kidney Diseases (2017) Vol. 71, Iss. 3, pp. 362-370
Open Access | Times Cited: 252
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity
Masato Furuhashi
AJP Endocrinology and Metabolism (2020) Vol. 319, Iss. 5, pp. E827-E834
Closed Access | Times Cited: 242
Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury
Hong-yong Su, Chen Yang, Dong Liang, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 148
Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review
Ching-Wei Tsai, Shih‐Yi Lin, Chin‐Chi Kuo, et al.
PLoS ONE (2017) Vol. 12, Iss. 1, pp. e0170393-e0170393
Open Access | Times Cited: 169
Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2
Daigo Toyoki, Shigeru Shibata, Emiko Kuribayashi‐Okuma, et al.
AJP Renal Physiology (2017) Vol. 313, Iss. 3, pp. F826-F834
Open Access | Times Cited: 117
No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study
Daniel M. Jordan, Hyon K. Choi, Marie Verbanck, et al.
PLoS Medicine (2019) Vol. 16, Iss. 1, pp. e1002725-e1002725
Open Access | Times Cited: 111
Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease
Markus Sellmayr, Moritz Roman Hernández Petzsche, Qiuyue Ma, et al.
Journal of the American Society of Nephrology (2020) Vol. 31, Iss. 12, pp. 2773-2792
Open Access | Times Cited: 102
Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy
Yingfeng Shi, Min Tao, Xiaoyan Ma, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 6
Open Access | Times Cited: 83
Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study
Cecilia Barnini, Elisa Russo, Giovanna Leoncini, et al.
Metabolites (2025) Vol. 15, Iss. 1, pp. 11-11
Open Access | Times Cited: 1
Pharmacological inhibition of autophagy by 3-MA attenuates hyperuricemic nephropathy
Jinfang Bao, Yingfeng Shi, Min Tao, et al.
Clinical Science (2018) Vol. 132, Iss. 21, pp. 2299-2322
Open Access | Times Cited: 73
Treatment of Hyperuricemia in Chronic Kidney Disease
Juan C. Ramírez‐Sandoval, Magdalena Madero
Contributions to nephrology (2018), pp. 135-146
Closed Access | Times Cited: 71
Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes
Sascha Pilemann-Lyberg, Tine W. Hansen, Nete Tofte, et al.
Diabetes Care (2019) Vol. 42, Iss. 6, pp. 1088-1094
Open Access | Times Cited: 67
How should we manage asymptomatic hyperuricemia?
Gérard Chalès
Joint Bone Spine (2018) Vol. 86, Iss. 4, pp. 437-443
Closed Access | Times Cited: 66
Induction of Autophagy by Pterostilbene Contributes to the Prevention of Renal Fibrosis via Attenuating NLRP3 Inflammasome Activation and Epithelial-Mesenchymal Transition
Ying‐Jan Wang, Yu-Ying Chen, Ching-Mao Hsiao, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 59
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
Yasir Waheed, Fan Yang, Dong Sun
The Korean Journal of Internal Medicine (2020) Vol. 36, Iss. 6, pp. 1281-1293
Open Access | Times Cited: 58
Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
Anna Pisano, Valeria Cernaro, Guido Gembillo, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2283-2283
Open Access | Times Cited: 50
3-MCPD and glycidol coexposure induces systemic toxicity and synergistic nephrotoxicity via NLRP3 inflammasome activation, necroptosis, and autophagic cell death
Pei-Wen Liu, Chung-I Li, K. C. Huang, et al.
Journal of Hazardous Materials (2020) Vol. 405, pp. 124241-124241
Open Access | Times Cited: 48
Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease
Scott E. Liebman, Thu H. Le
Nutrients (2021) Vol. 13, Iss. 1, pp. 266-266
Open Access | Times Cited: 40
Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling
Andrea Tóth, Dávid Máté Csiki, Béla Nagy, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 24
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Thomas Bais, Ron T. Gansevoort, Esther Meijer
Drugs (2022) Vol. 82, Iss. 10, pp. 1095-1115
Open Access | Times Cited: 24
Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet
Jiong Cui, Pianpian Hong, Zhenzhou Li, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110353-110353
Closed Access | Times Cited: 13
Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study
Yasir Waheed, Fan Yang, Jie Liu, et al.
Frontiers in Nephrology (2025) Vol. 5
Open Access
Eurycoma longifolia alkaloid components ameliorate hyperuricemic nephropathy via regulating serum uric acid level and relieving inflammatory reaction
Dan Wang, Lin Liu, Kaiwen Li, et al.
Journal of Natural Medicines (2023) Vol. 77, Iss. 4, pp. 867-879
Closed Access | Times Cited: 12
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats
Shinichiro Asakawa, Shigeru Shibata, Chikayuki Morimoto, et al.
Oxidative Medicine and Cellular Longevity (2017) Vol. 2017, Iss. 1
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top